2NN & CHARM Long-Term Follow-up Study

• Status: Completed
• Trial end date: 2007-04-01
• Target enrollment: 0
• Participant gender: All

Summary

It is desirable to obtain extended follow up data on subjects who participated in the 2NN study and the CHARM study in order to see if the beneficial effect of using nevirapine continues up to 144 weeks of treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: International Antiviral Therapy Evaluation Center
• Collaborator: Boehringer Ingelheim
• Treatments: Efavirenz; Lamivudine; Nevirapine; Stavudine

Criteria

Inclusion Criteria:

• Participation in the original 2NN or CHARM study

Exclusion Criteria:

• None